Sub Q Entyvio Hits Speed Bump After US Complete Response
Queries ‘Unrelated’ To Clinical Data
Executive SummaryQuestions from FDA may delay progress to US approval of Takeda's more convenient formulation of blockbuster Entyvio.
You may also be interested in...
Celltrion plans to launch its new subcutaneous formulation of Remsima in Europe next year beginning with Germany and then to get approvals for all indications by mid-2020. It has indicated that prices will be higher than first-line anti-TNF treatments but competitive with second-line rheumatoid arthritis treatments, as it pursues a strategy to gain substantial market share.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.